Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1914-1922

  Zhang, Xiaoyue ^a,b   Wang, Zhaopeng ^a   Wang, Zhaoxia ^a   Zhang, Yueying ^a   Jia, Qing ^a   Wu, Licun ^c   Zhang, Weidong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF JINAN   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Aspirin; Lymphangiogenesis; Microvessel density; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; FLUOROURACIL; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENZYME INHIBITION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LYMPHANGIOGENESIS; LYMPHATIC VESSEL DENSITY; MALE; MICROVESSEL DENSITY; MOLECULAR MECHANICS; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SARCOMA; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; LYMPH VESSEL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RANDOMIZATION; SARCOMA, EXPERIMENTAL; VASCULARIZATION;

ANIMALS; ASPIRIN; FLUOROURACIL; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; SARCOMA, EXPERIMENTAL; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895703636     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2339     Document Type: Article

References (29)

1. Vinogradova Y, Hippisley-Cox J, Coupland C, et al: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 133: 393-402, 2007. (Pubitemid 47187349)
2. Doherty GA and Murray FE: Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? Expert Opin Ther Targets 13: 209-218, 2009.
3. Rostom A, Dube C, Lewin G, et al: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376-389, 2007. (Pubitemid 351650598)
4. Rothwell PM, Price JF, Fowkes FG, et al: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risk sand benefits in 51 randomised controlled trials. Lancet 379: 1602-1612, 2012.
5. Li S, Miner K, Fannin R, et al: Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 92: 622-627, 2004. (Pubitemid 38183153)
6. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002. (Pubitemid 34196319)
7. Dube C, Rostom A, Lewin G, et al: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 365-375, 2007. (Pubitemid 351650597)
8. Sadeghi S, Bain CJ, Pandeya N, et al: Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17: 1169-1178, 2008.
9. Gee JR, Jarrard DF, Bruskewitz RC, et al: Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. BJU Int 103: 736-739, 2009.
10. Kelly JP, Coogan P, Strom BL, et al: Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 17: 322-327, 2008. (Pubitemid 351566347)
11. Alfonso LF, Srivenugopal KS, Arumugam TV, et al: Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 34: 597-608, 2009.
12. Kim SR, Bae MK, Kim JY, et al: Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Communm 387: 342-347, 2009.
13. Iwama T: NSAIDs and colorectal cancer prevention. J Gastroenterol 44: 72-76, 2009.
14. Dannenberg AJ, Altorki NK, Boyle JO, et al: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001. (Pubitemid 33586867)
15. Wang D, Mann JR and DuBois RN: The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128: 1445-1461, 2005. (Pubitemid 40712194)
16. Alitalo K, Tammela T and Petrova TV: Lymphangiogenesis in development and human disease. Nature 438: 946-953, 2005. (Pubitemid 43093960)
17. Achen MG and Stacker SA: Tumor lymphagiogenesis and metastatic spread-new players begin to emerge. Int J Cancer 119: 1755-1760, 2006. (Pubitemid 44356830)
18. Pepper MS, Tille JC, Nisato R, et al: Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314: 167-177, 2003. (Pubitemid 37409922)
19. Yonemura Y, Endo Y, Fujita H, et al: Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5: 1823-1829, 1999. (Pubitemid 29334464)
20. Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64: 554-564, 2004.
21. Timoshenko AV, Chakraborty C, Wagner GF, et al: COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 94: 1154-1163, 2006.
22. Siironen P, Ristimaki A, Narko K, et al: VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer 13: 465-473, 2006. (Pubitemid 43886669)
23. Soumaoro LT, Uetake H, Takagi Y, et al: Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 49: 392-398, 2006.
24. Zhang J, Ji J, Yuan F, et al: Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients. Biomed Pharmacother 59: S285-S288, 2005.
25. Weider N, Carroll PR, Flax J, et al: Tumor angiogenesis correlation with metastasis in invasive prostate carcinoma. Am J Pathol 143: 755-761, 1993.
26. Borthwick GM, Johnson AS, Partington M, et al: Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20: 2009-2016, 2006. (Pubitemid 44953901)
27. Pillinger MH, Capodici C, Rosenthal P, et al: Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 95: 14540-14545, 1998. (Pubitemid 28549403)
28. Saad RS, Kordunsky L, Liu YL, et al: Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 19: 1317-1323, 2006. (Pubitemid 44423078)
29. lwata C, Kano MR, Komuro A, et al: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67: 10181-10189, 2007.